


## PHARMACEUTICAL 2021

## Regen BioPharma Inc Rank 29 of 409





## PHARMACEUTICAL 2021



## Regen BioPharma Inc Rank 29 of 409

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 613% points. The greatest weakness of Regen BioPharma Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 1,604% points.

The company's Economic Capital Ratio, given in the ranking table, is 153%, being 508% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	103
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,458
Liabilities, Non-Current	0
Other Assets	20
Other Compr. Net Income	0
Other Expenses	56
Other Liabilities	0
Other Net Income	3,624
Property and Equipment	0
Research and Development	13
Revenues	110
Selling, General and Administrative Expense	250

Output Variable	Value in 1000 USD
Assets	123
Liabilities	7,458
Expenses	319
Stockholders Equity	-7,335
Net Income	3,414
Comprehensive Net Income	3,414
Economic Capital Ratio	153%